The United Kingdom and the United States have signed a major bilateral deal that will guarantee no import taxes on British drug exports being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise spending on medicines through the public health system. This pledge ensures that import taxes on these crucial products will remain at zero for a period of the next three years.
This deal is in response to recent threats to dramatically increase duties on branded drug products, with figures mentioned up to one hundred percent.
"This deal with the United Kingdom reinforces the worldwide climate for new treatments and introduces long-overdue balance to transatlantic medicine commerce," a statement declared.
Economic Significance
Drugs are one of the Britain's most significant export categories to the America, which is clearly the largest buyer for leading companies like GSK and AstraZeneca.
Export figures show that in the year prior to September, the UK sold pharmaceutical products worth billions to the US. This figure represented a significant portion of total UK exports in that period.
"This deal secures jobs, increases funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Key NHS Changes
The agreement entails several notable commitments from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to double overall public funding on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must pay back to the NHS to control costs will be restricted at 15%. In the past, refunds topped 20%.
Recent Tensions
This agreement takes place against a protracted row between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that American patients were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been paused or scrapped, while major funding commitments have been announced toward US facilities.
The Science Minister stated that the NHS must spend more on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the past decade.
